News | January 25, 2022
USFDA rejects Merck’s gefapixant; gain approval in Japan
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
The brand is now available pan-India through their distribution partner
The drug will be marketed under the brand name Molnaflu
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Subscribe To Our Newsletter & Stay Updated
